Table 4.
HR | 95% CI | p | |
---|---|---|---|
Age | 1.012 | 0.986–1.038 | 0.3730 |
Gender | |||
Male | 1.000 (referent) | ||
Female | 0.905 | 0.536–1.528 | 0.7088 |
Ethnicity | |||
Caucasian | 1.000 (referent) | ||
Black | 0.703 | 0.244–2.023 | 0.5135 |
Hispanic | 0.890 | 0.390–2.032 | 0.7815 |
Asian | 0.655 | 0.244–1.755 | 0.3998 |
Socioeconomic status | 0.936 | 0.765–1.145 | 0.5915 |
Clinical stage | |||
Localized | 1.000 (referent) | ||
Regional | 2.717 | 0.781–9.451 | 0.1161 |
Metastatic | 4.690 | 1.445–15.216 | 0.0101 |
Oncologic resection | |||
No | 1.000 (referent) | ||
Yes | 0.369 | 0.183–0.747 | 0.0056 |
Any radiation | |||
No | 1.000 (referent) | ||
Yes | 0.474 | 0.242–0.927 | 0.0292 |
Any chemotherapy | |||
No | 1.000 (referent) | ||
Yes | 0.530 | 0.300–0.935 | 0.0285 |
The numbers in bold are those which are statistically significant, i.e. p < 0.05
HR hazard ratio for death, 95% CI 95% confidence interval